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Introduction
Children are expected to have an 
average of one to three episodes of 
diarrhoea per year, with incidences 
rates as high as 10 per year for 
children in poor, less developed 
locales. 1 While most parents and 
practitioners consider diarrhoea a 
minor ailment rather than a deadly 
condition, diarrhoeal diseases are 
estimated to cause 20-25% mortality 
among children less than five years 
in the developing world.1 The most 
important aetiological agents of 
diarrhoea are viral and bacterial, 
with rotavirus and enterotoxigenic 
E. coli frequently identified among 
children in developing countries and 
viral aetiologies playing a larger role 
in more developed countries with 
improved sanitation and access to 
clean water.2, 3 
Prevalence
Rotavirus, an icosahedral, non-
enveloped virus belonging to the 
Reoviridae family has a segmented 
genome of 11 distinct segments of 
dsRNA enclosed by three protein 
layers. In Africa alone, recent 
estimates consign 140 000 – 150 
000 deaths per year due to rotavirus 
disease in children less than five 
years.4 Rotavirus accounts for 20-
25% of all deaths due to diarrhoea 
and 6% of all deaths among 
children younger than five years.5, 6 
Virtually every child will have at least 
one rotavirus infection in the first five 
years of life and because public 
health interventions to provide 
clean water and improved sanitation 
will not decrease the incidence of 
rotavirus disease, vaccines were 
developed as the primary prevention 
tool against severe dehydrating 
rotavirus diarrhoea. 
Clinical
Rotavirus diarrhoea affects the 
young of human and animals, and 
viral particles are transmitted by the 
faecal-oral route, although indirect 
evidence also suggests that they 
may also be transmitted by the 
respiratory route.6, 7  The incubation 
period is estimated at less than 
48 hours and the virus attacks the 
mature enterocytes on the tips of 
the small intestinal villi. An infection 
usually begins with a sudden onset 
of vomiting lasting one to two days 
and watery diarrhea lasting for 
approximately five days. These 
symptoms are usually accompanied 
by several days of fever (37.9°C or 
greater) and dehydration.6 Rotavirus 
infections are seasonal and occur 
in the cool, dry winter months in 
temperate zones i.e. in South Africa 
the rotavirus season runs from late 
March, early April to July or August. 
The peak incidence of rotavirus 
infection in children in developing 
countries occurs between 6 and 
11 months of age, while children 
in developed countries tend to 
become infected later i.e. during 
their second year of life. In neo-
nates, rotavirus infections may 
often be asymptomatic but after 3 
months of age rotavirus infections 
are more likely to be symptomatic 
and result in severe life-threatening 
dehydration.8 Reinfection with rota-
virus is common during childhood, 
however, the severity of the disease 
rapidly decreases after the first 
infection and no child experiences 
the severe form of the disease after 
the second rotavirus infection.9
Vaccines
Two live, attenuated rotavirus 
vaccine candidates have been 
developed and licensed by 
multinational pharmaceutical com-
panies. RotaRix™, developed 
by GlaxoSmithKline Biologicals 
(Rixensart, Belgium), is a serotype 
G1P[8] human strain, based on the 
observation that natural rotavirus 
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infections protect children against 
subsequent severe dehydrating 
diarrhoea. Vaccine trials in Fin-
land, Latin America and Asia 
have indicated 68-90% efficacy 
against severe rotavirus diarrhoea 
and 56-73% efficacy against any 
rotavirus diarrhoea.10 In South 
Africa, two vaccine trials assessing 
interference with oral polio vaccine 
and optimum vaccine dose have 
been completed and an additional 
two trials assessing vaccine efficacy 
and safety in HIV-positive babies will 
be completed by the end of 2006 or 
beginning of 2007.  
The GlaxoSmithKline rotavirus 
vaccine was licensed by the 
European Commission in February 
2006 and an additional 35 licenses 
have been granted worldwide 
including Mexico, Brazil, Philippines, 
Singapore and Australia. Further-
more, Rotarix™ has been filed for 
approval in 75 countries, the United 
States and South Africa among 
these. Rotarix™ was registered 
in South Africa in July 2006 and 
is now available on a two dose 
schedule to children in the private 
sector. Recently, Brazil, Panama 
and Venezuela have included the 
rotavirus vaccine in their national 
official vaccination calendars and 
vaccination with RotarixTM will be 
available free at public health clinics 
in these countries (GSK Press 
Release 05 May, 2006). 
The second candidate, 
RotaTeq®, developed by Merck 
(Blue Bell, PA, USA), is a pentavalent 
bovine-human reassortant con-
taining the surface proteins for 
serotypes G1, G2, G3, G4 and 
P[8] while retaining a bovine (WC3) 
genome backbone.11 The vaccine 
has been based on the observation 
that candidate vaccines were 
successful in inducing protection 
against rotavirus in areas where the 
prevalent circulating strains was the 
same as that of the vaccine strain.12 
Vaccine trials have been conducted 
from 2001 to 2004 in 11 countries 
(the United States, Belgium, Costa 
Rica, Finland, Germany, Guatemala, 
Italy, Jamaica, Mexico, Sweden and 
Taiwan) and results show a 98% 
efficacy against severe rotavirus 
diarrhoea and 74% efficacy against 
any rotavirus diarrhoea.13 
RotaTeq® was licensed by 
the American Food and Drug 
Administration in February 2006 
and is the only rotavirus vaccine 
currently available to the American 
public. In addition, RotaTeq® has 
received a positive opinion from the 
Committee for Medicinal Products 
for Human Use (CHMP), the 
Scientific Committee of the European 
Medicines Agency (EMEA) and 
the European Commission could 
grant marketing authorization for 
the vaccine anytime from July 2006 
onwards (Sanofi Pasteur MSD Press 
Release 02 May, 2006). RotaTeq® 
has been filed for licensure in more 
than 50 countries including South 
Africa (ACIP Press Release 21 
February, 2006). RotaTeq® has 
not yet been tested in an African 
setting but Merck is working with the 
Program for Appropriate Technology 
in Health (PATH) to conduct clinical 
studies in developing countries and 
at least one vaccine trial is planned 
to start by the end of 2006 (Merck 
Press Release 07 December, 
2005).
Conclusion
The massive impact of rotavirus-
associated diarrhoea on the chil-
dren of South Africa and Africa has 
long been acknowledged.14,15 It is, 
therefore, reassuring to know that 
an effective properly administered 
rotavirus vaccine could potentially 
prevent 170 000–210 000 childhood 
deaths per year or about one in 20 
deaths in children under five years of 
age.16 While the rotavirus vaccines 
will not prevent all forms of diarrhoea 
in children it will prevent children from 
developing rotavirus-associated 
severe dehydrating diarrhoea that 
requires hospitalization and avert 
deaths due to this common child-
hood pathogen.          
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